Rapid Communication - Journal of Cardiovascular Medicine and Therapeutics (2022) Volume 6, Issue 6
Adenosine receptors and their cardiac effects in atrial fibrillation
Department of cardiology, Timone University Hospital, Marseille, France
- *Corresponding Author:
- Riccardo Sarzani
Department of cardiology
Timone University Hospital
Received: 26-Oct-2022, Manuscript No. AACMT-22-81836; Editor assigned: 27-Oct-2022, PreQC No. AACMT-22-81836(PQ); Reviewed: 10-Nov-2022, QC No. AACMT-22-81836; Revised: 16-Nov-2022, Manuscript No. AACMT-22-81836(R); Published: 24-Nov-2022, DOI:10.35841/aacmt-6.6.129
Citation: Maille B. Adenosine receptors and their cardiac effects in atrial fibrillation. J Cardiovasc Med Ther. 2022;6(6):129
Atrial fibrillation (AF) is a multifactorial supported cardiovascular arrhythmia, and it is currently viewed as a truly overall general medical problem, influencing in excess of 50 million people. Since this normal arrhythmia, in clinical practice, is related with significant poor clinical results, for example, left ventricular brokenness, cardiovascular breakdown or stroke, serious examination has been created to comprehend the physiopathology of AF better. In spite of the significant headway that has been made in the location and the executives of AF, the fundamental atomic systems related with the beginning of atrial fibrillation and its movement stays still hazy. Among these atomic components, the ramifications of the adenosinergic framework in AF has expanded, since the aggregation of trial information proposes that the expansion in the adenosine blood level and the renovating articulation of the adenosine receptors may be essential for the AF pathophysiology. Tragically, the adenosinergic framework actually has a Janus face in cardiovascular arrythmias, since adenosine can have both antiarrhythmic and pro arrhythmic activities, alongside adenosine receptors, which can prompt either profibrotic or anti fibrotic impacts. Moreover, whether adenosinergic framework aggravations are the reason or the outcome of AF isn't yet explained .
As the way to creating imaginative treatments that limit the beginning and movement of AF is to completely comprehend the hidden atomic components of AF, the point of the current story survey was to report the latest advances on the likely job of the adenosinergic framework in the pathophysiology of AF. Subsequent to portraying the adenosinergic framework's flagging and the pathophysiology of AF, this survey centers around the arrhythmogenic impacts of adenosine and finishes up with the relationship between the AF risk factors and adenosinergic framework unsettling influence. Since Drury and Szent-Gyorgyi previously noticed the heart impact of adenine compounds in 1929 and Burnstock proposed the idea of extracellular purinergic motioning in 1972, adenosine has arisen as a significant flagging particle with pleiotropic activities, remembering impacts for the cardiovascular framework .
This universal purine nucleoside comes predominantly from ATP dephosphorylation when tissue energy necessities increment, for example, during hypoxia, ischemia or irritation. The methionine cycle can add to intracellular adenosine arrangement in the heart by the hydrolysis of S-adenosylhomocysteine. Be that as it may, ATP hydrolysis is viewed as the principal wellspring of adenosine optional because of the extracellular dephosphorylation outpouring of ATP by the progressive activity of a layer secured ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and the ecto-5'- nucleotidase (CD73). Thus, all circumstances related with a gigantic arrival of adenine nucleotides (e.g., cell harm, platelet conglomeration, and vascular shear pressure) can quickly build the degree of adenosine from 0.4-0.8 µmol/L under resting physiological circumstances to more than 1.0 µmol/L in pathologic circumstances, for example, neutrally intervened syncope or cardiogenic shock .
Blood convergences of adenosine are restricted in existence by its catabolism and reabsorption by adjusting nucleoside carriers (ENTs), especially in red platelets. Adenosine deaminase (ADA), which is available in many cells and on the outer layer of mononuclear cells (MC-ADA), switches adenosine over completely to inosine, which is used to uric corrosive, its last catabolite. Besides, adenosine kinase can phosphorylate intracellular adenosine and convert it into adenosine monophosphate (AMP). Thus, the half-existence of adenosine is short (10-30 s) due, outstandingly, to the reality of its fast take-up by erythrocytes and its deamination by adenosine deaminase, and its pace of turnover rate is 1.5 nmol/mL/min. During hypoxia, ischemia or irritation, ATP digestion is changed prompting expanded creation of adenosine, which is related with a decline in its rephosphorylation. Irritation or hypoxia can balance the adenosinergic framework on account of the record factor NF-κB, which builds the record of adenosine receptors and hypoxia-inducible variable 1α (HIF-1α) qualities .
In hypoxic conditions, the proteasomal debasement of prolyl-hydroxylase considers the atomic movement of the record factor HIF-1α to prompt the record of various qualities, including those for adenosine receptors and CD73 and NF-κB, and to stifle the record of ENT and adenosine kinase qualities. Hence, expanded adenosine plasma fixations have been very much announced in ischemic or fiery illnesses, like coronary vein or ischemic heart sicknesses and aspiratory irritation. Adenosine receptors are partitioned in four G protein-coupled receptors, named A1 (A1R), A2A (A2AR), A2B (A2BR) and A3 (A3R) receptors, which are arranged by their essential succession, their related G-protein and their pharmacological profile (restricting liking of agonists and adversaries). A1R and A3R are coupled to the Gi/o proteins prompting the restraint of adenylyl cyclase (AC), though A2AR and A2BR are related to Gs proteins, which animate the adenylyl cyclase and increment the intracellular creation of cyclic-AMP (cAMP). A1R and A2AR have a high partiality for adenosine with a higher restricting proclivity of A1R. A2BR and A3R have a lower partiality for adenosine .
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
- Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics—2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153-639.
- Jozsef Szentmiklosi A, Galajda Z, et al. The Janus face of adenosine: antiarrhythmic and proarrhythmic actions. Curr Pharm Des. 2015;21(8):965-76.
- Guieu R, Deharo JC, Maille B, et al. Adenosine and the cardiovascular system: The good and the bad. J Clin Med. 2020;9(5):1366.
- Colgan SP, Eltzschig HK, Eckle T, et al. Physiological roles for ecto-5’-nucleotidase (CD73). Purinerg Signal. 2006;2(2):351-60.